ReviewGenes & genomics2025
Emerging technologies and clinical translation of urine-based liquid biopsy in urological cancers.
Review in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making-A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Urine-based liquid biopsy represents a transformative, non-invasive diagnostic approach that enables the molecular profiling of tumor-derived biomarkers shed into the urinary tract. By overcoming the limitations of traditional tissue biopsies, this methodology facilitates early cancer detection, real-time monitoring of therapeutic response, and longitudinal disease surveillance. This review provides a comprehensive overview of current urine-based liquid biopsy platforms, with a focus on protein and RNA biomarkers in urological cancers. We highlight the clinical relevance of these biomarkers and discuss technological innovations-including multi-omics integration, machine learning applications, and point-of-care testing-that are expanding their diagnostic utility. By leveraging the unique anatomical accessibility of urological malignancies via urine sampling, this field is poised to significantly enhance precision oncology.
Indexed as
Identifiers
40996489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.